Home> Products> Inhibitors> EMD-1214063-CAS 1100598-32-0
price inquiry for CAS:1100598-32-0, Product:EMD-1214063

EMD-1214063 CAS: 1100598-32-0

Category: Inhibitors
Product Name: EMD-1214063
Cat No: I000414
CAS No: 1100598-32-0
Synonyms: 3-[1-[[3-[5-[(1-methylpiperidin-4-yl)methoxy]pyrimidin-2-yl]phenyl]methyl]-6-oxopyridazin-3-yl]benzonitrile
Molecular Formula: C29H28N6O2
Molecular Weight: 492.6
SMILES: CN1CCC(COC2=CN=C(C3=CC=CC(CN4C(C=CC(C5=CC(C#N)=CC=C5)=N4)=O)=C3)N=C2)CC1
InChI: None
InChIKey: AHYMHWXQRWRBKT-UHFFFAOYSA-N
Solubility: DMSO: ≤ 27 mg/mL
Target: c-MET
IC50: 4 nM [1]
Storage: powder
CAS 1100598-32-0,EMD-1214063
  • Description

EMD 1214063 is a potent and selective c-Met inhibitor with IC50 of 4 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer.
IC50 Value: 4 nM [1]
Target: c-Met
in vitro: EMD 1214063 inhibits HGF-induced c-Met phosphorylation in A549 cells with IC50 of 6 nM. Treatment with EMD 1214063 induces a marked reduction of c-Met–constitutive phosphorylation in EBC-1 cells with IC50 of 9 nM. EMD 1214063 effectively blocka phosphorylation of the major downstream effectors of the c-Met enzyme, such as Grb2, Gab1, Sos, PLCγ, and phosphoinositide 3-kinase, in EBC-1, MKN-45, and Hs746T cells in the range of 1 to 10 nM. EMD 1214063 considerably inhibits the viability of MKN-45 cells with IC50 of less than 1 nM. Treatment with EMD 1214063 (as low as 0.1 nM) inhibits HGF-induced NCI-H441 cell migration, whereas concentrations of 100 nM to 1 μM almost completely prevents it.
in vivo: EMD 1214063 treatment, at doses of 10 mg/kg or more, results in more than 90% inhibition of c-Met phosphorylation in Hs746T xenograft tumor for a period of at least 72 hours. EMD 1214063 induces more than 50% reduction of cyclin D1 expression, which persists after 96 hours upon treatment with doses of 100 mg/kg. A transient induction of p27 and cleaved caspase-3 are also observed upon treatment with EMD 1214063. EMD 1214063 (15 mg/kg, daily) treatment induces complete regression of gastric carcinoma xenografts Hs746T, in which c-Met is amplified, overexpressed, and activated in a ligand-independent fashion.

  • Spec

Appearance:Solid powder
Purity: > 98%

  • References

1:Clin Cancer Res. 2013 Jun 1;19(11):2941-51. doi: 10.1158/1078-0432.CCR-12-3247. Epub 2013 Apr 3. EMD 1214063 and EMD 1204831 constitute a new class of potent and highly selective c-Met inhibitors.Bladt F,Faden B,Friese-Hamim M,Knuehl C,Wilm C,Fittschen C,Grädler U,Meyring M,Dorsch D,Jaehrling F,Pehl U,Stieber F,Schadt O,Blaukat A, PMID: 23553846 DOI: 10.1158/1078-0432.CCR-12-3247
Abstract: PURPOSE: The mesenchymal-epithelial transition factor (c-Met) receptor, also known as hepatocyte growth factor receptor (HGFR), controls morphogenesis, a process that is physiologically required for embryonic development and tissue repair. Aberrant c-Met activation is associated with a variety of human malignancies including cancers of the lung, kidney, stomach, liver, and brain. In this study, we investigated the properties of two novel compounds developed to selectively inhibit the c-Met receptor in antitumor therapeutic interventions.EXPERIMENTAL DESIGN: The pharmacologic properties, c-Met inhibitory activity, and antitumor effects of EMD 1214063 and EMD 1204831 were investigated in vitro and in vivo, using human cancer cell lines and mouse xenograft models.RESULTS: EMD 1214063 and EMD 1204831 selectively suppressed the c-Met receptor tyrosine kinase activity. Their inhibitory activity was potent [inhibitory 50% concentration (IC50), 3 nmol/L and 9 nmol/L, respectively] and highly selective, when compared with their effect on a panel of 242 human kinases. Both EMD 1214063 and EMD 1204831 inhibited c-Met phosphorylation and downstream signaling in a dose-dependent fashion, but differed in the duration of their inhibitory activity. In murine xenograft models, both compounds induced regression of human tumors, regardless of whether c-Met activation was HGF dependent or independent. Both drugs were well tolerated and induced no substantial weight loss after more than 3 weeks of treatment.CONCLUSIONS: Our results indicate selective c-Met inhibition by EMD 1214063 and EMD 1204831 and strongly support clinical testing of these compounds in the context of molecularly targeted anticancer strategies.©2013 AACR


price inquiry for CAS:1100598-32-0, Product:EMD-1214063